Abstract
Combination therapy in the treatment of metastatic melanoma has more durable response rate rather than monotherapy. Although combined target therapy commonly causes a wide spectrum of adverse events, they are usually manageable. Toxic epidermal necrolysis represents severe mucocutaneous reaction, usually triggered by medications. Here we present a first case of toxic epidermal necrolysis induced by combined target therapy (vemurafenib plus cobimetinib). The case was observed in a young patient with BRAF mutant melanoma who was started on first-line metastatic immunotherapy with pembrolisumab. In conclusion, we emphasize the need to always compare drug efficacy with its potential adverse effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.
Sanchez JN, Wang T, Cohen MS. BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers. Drugs. 2018;78(5):549–66.
Faghfuri E, Nikfar S, Niaz K, Faramarzi MA, Abdollahi M. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors. Expert Opin Drug Metab Toxicol. 2018;14:317–30.
Dréno B, Ribas A, Larkin J, Hauschild A, Thomas L, Grob JJ, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017;28:1137–44.
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17:1248–60.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Poduje, S., Brozić, J.M., Prkačin, I., Aždajić, M.D., Goren, A. (2020). Serious Adverse Event Caused by Combined Target Therapy. In: Lotti, T., Tirant, M., Wollina, U. (eds) Clinical Cases in Melanoma. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-50820-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-50820-3_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-50819-7
Online ISBN: 978-3-030-50820-3
eBook Packages: MedicineMedicine (R0)